Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer
Condition(s):HER2-positive Refractory Advanced CancerLast Updated:February 17, 2017Completed
Hide Studies Not Open or Pending
Condition(s):HER2-positive Refractory Advanced CancerLast Updated:February 17, 2017Completed
Condition(s):Advanced Malignant NeoplasmLast Updated:October 30, 2023Recruiting
Condition(s):AstheniaLast Updated:May 9, 2017Terminated
Condition(s):Primary Stage IV Hepatobiliary; Esophageal; Colorectal Cancer; Glioblastoma; Cancer of Stomach; Cancer of Pancreas; Melanoma; Head or Neck Cancer; Stage III; Stage IV; Lung Cancers; Pancreatic CancersLast Updated:October 1, 2019Completed
Condition(s):Breast Cancer; Head and Neck Squamous Cell Carcinoma; Non Small Cell Lung Cancer; Hepatocellular Cancer; Colorectal Cancer; Gastric Adenocarcinoma; Melanoma; Advanced CancerLast Updated:November 22, 2023Active, not recruiting
Condition(s):Lymphoma; Advanced Solid TumorLast Updated:February 8, 2024Suspended
Condition(s):Advanced CancersLast Updated:February 25, 2019Completed
Condition(s):Metastatic Lung Cancer; Metastatic Gastrointestinal CancerLast Updated:March 5, 2024Recruiting
Condition(s):CancerLast Updated:April 23, 2012Completed
Condition(s):Advanced CancersLast Updated:June 7, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.